One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Shreelaxmi Gavas, Sameer Quazi, Tomasz M. M Karpiński
Cancer is one of the leading causes of death and morbidity with a complex pathophysiology. Traditional cancer therapies include chemotherapy, radiation therapy, targeted therapy, and immunotherapy. However, limitations such as lack of specificity, cytotoxicity, and multi-drug resistance pose a substantial challenge for favorable cancer treatment. The advent of nanotechnology has revolutionized the arena of cancer diagnosis and treatment. Nanoparticles (1-100 nm) can be used to treat cancer due to their specific advantages such as biocompatibility, reduced toxicity, more excellent stability, enhanced permeability and retention effect, and precise targeting. Nanoparticles are classified into several main categories. The nanoparticle drug delivery system is particular and utilizes tumor and tumor environment characteristics. Nanoparticles not only solve the limitations of conventional cancer treatment but also overcome multidrug resistance. Additionally, as new multidrug resistance mechanisms are unraveled and studied, nanoparticles are being investigated more vigorously. Various therapeutic implications of nanoformulations have created brand new perspectives for cancer treatment. However, most of the research is limited to in vivo and in vitro studies, and the number of approved nanodrugs has not much amplified over the years. This review discusses numerous types of nanoparticles, targeting mechanisms, and approved nanotherapeutics for oncological implications in cancer treatment. Further, we also summarize the current perspective, advantages, and challenges in clinical translation.
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Gavas, S., Quazi, S., & Karpiński, T. M. M. (2021). Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Research Letters, 16(1), 173. https://doi.org/10.1186/s11671-021-03628-6
Gavas, Shreelaxmi, et al. "Nanoparticles for Cancer Therapy: Current Progress and Challenges." Nanoscale Research Letters, vol. 16, no. 1, 2021, pp. 173, https://doi.org/10.1186/s11671-021-03628-6.
Gavas, Shreelaxmi, Sameer Quazi, and Tomasz M. M Karpiński. "Nanoparticles for Cancer Therapy: Current Progress and Challenges." Nanoscale Research Letters 16, no. 1 (2021): 173. https://doi.org/10.1186/s11671-021-03628-6.
Gavas S., Quazi S., Karpiński T. M. M. Nanoparticles for Cancer Therapy: Current Progress and Challenges // Nanoscale Research Letters. — 2021. — Vol. 16, № 1. — P. 173. — URL: https://doi.org/10.1186/s11671-021-03628-6
@article{gavas2021nanoparticles,
title = {{Nanoparticles for Cancer Therapy: Current Progress and Challenges}},
author = {Shreelaxmi Gavas and Sameer Quazi and Tomasz M. M Karpiński},
journal = {Nanoscale Research Letters},
year = {2021},
volume = {16},
number = {1},
pages = {173},
doi = {10.1186/s11671-021-03628-6},
url = {https://doi.org/10.1186/s11671-021-03628-6}
}TY - JOUR AU - Gavas, Shreelaxmi AU - Quazi, Sameer AU - Karpiński, Tomasz M. M TI - Nanoparticles for Cancer Therapy: Current Progress and Challenges JO - Nanoscale Research Letters VL - 16 IS - 1 SP - 173 PY - 2021 DA - 2021/12/01 DO - 10.1186/s11671-021-03628-6 UR - https://doi.org/10.1186/s11671-021-03628-6 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.